AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Electronic Study for Anastrozole Pharmacovigilance Evaluation
Completed
- Conditions
- Early Breast Cancer
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1850
- Registration Number
- NCT00558168
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Phase 2
Completed
- Conditions
- Breast CancerProstate CancerBone Neoplasms
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT00558272
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00556023
- Locations
- 🇮🇹
Research Site, Roma, Italy
Patient's Anastrozole Compliance to Therapy Programme
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4923
- Registration Number
- NCT00555867
Renal Impairment in Type 2 Diabetic Subjects
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00554450
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 896
- Registration Number
- NCT00554229
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT00546520
- Locations
- 🇬🇧
"Altana Pharma/Nycomed", London, United Kingdom
Drug Interaction With Metformin
Phase 1
Completed
- Conditions
- Healthy Male and Female Subjects
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00546741
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Impact of GERD on Daily Life (NIS)
Completed
- Conditions
- GERD
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2001
- Registration Number
- NCT00545883
- Locations
- 🇧🇪
Research Site, Zichem, Belgium
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
Phase 4
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00544986
© Copyright 2025. All Rights Reserved by MedPath